ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $11.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-24
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-12-31 was $1.60M, a 14.29% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-09-30 was $2.60M, a 4.00% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $2.40M, a 52.00% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $3.50M, a 337.50% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $11.20M, a 19.15% increase from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $9.40M, a 7.84% decline from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $10.20M, a 6.25% increase from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $9.60M, a 300.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.20M 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $9.40M 10-K · filed 2026-03-24 | |||
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $4.20M derived: sum of 2 quarters · filed 2025-03-18 | $6.60M derived: sum of 3 quarters · filed 2025-03-18 | $10.20M 10-K · filed 2025-03-18 |
| 2023-09-30 | $2.60M 10-Q · filed 2023-11-14 | $5.00M derived: sum of 2 quarters · filed 2023-11-14 | $8.60M 10-Q · filed 2023-11-14 | $9.90M derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | $2.40M 10-Q · filed 2023-08-14 | $6.00M 10-Q · filed 2023-08-14 | $7.30M derived: sum of 3 quarters · filed 2024-03-21 | $9.80M derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | $3.50M 10-Q · filed 2023-05-15 | $4.90M derived: sum of 2 quarters · filed 2024-03-21 | $7.40M derived: sum of 3 quarters · filed 2024-03-21 | $12.40M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $3.90M derived: sum of 2 quarters · filed 2024-03-21 | $8.90M derived: sum of 3 quarters · filed 2024-03-21 | $9.60M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.50M 10-Q · filed 2023-11-14 | $7.50M derived: sum of 2 quarters · filed 2023-11-14 | $8.20M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $5.00M 10-Q · filed 2023-08-14 | $5.80M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $800.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $2.40M 10-K · filed 2023-03-30 | |||
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $100.00K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |